Brainomix
AI imaging solutions that support clinicians to make faster, more confident treatment decisions from any imaging modality in the acute stroke pathway.
Company Overview
Since launching as a University of Oxford spin-out in 2010, Brainomix have developed award-winning AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions.
Brainomix drives improvement in patient outcomes by enhancing doctors’ decisions and working with pharmaceutical companies to translate treatments into clinical practice.
Brainomix 360 (called e-Stroke outside of the U.S.) is a comprehensive AI imaging suite of solutions that supports clinicians to make faster, more confident treatment decisions from any imaging modality in the acute stroke pathway.
Modalities
Subspecialities
Applications available
e-ASPECTS
Non-contrast brain CT analysis that automatically generates an ASPECTS score.
CE
FDA
CT
Neuro
e-CTA
Decision support tool that helps the assessment of collaterals on CT Angiography.
CE
FDA
CT
Neuro
e-CTP
CT perfusion analysis tool that helps identify and estimate ischemic core and tissue-at-risk.
CE
FDA
CT
Neuro
To find out more about Brainomix’s solutions, or the 100+ other applications on the Blackford Platform, book a discovery call with our team.
Book a meeting
We’d welcome the opportunity to learn more about your AI needs and to explain how partnering with Blackford can drive efficiency and provide ongoing value.
Book a Meeting